The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1258
Aliskiren (Tekturna) for Hypertension
The full article is available to subscribers Subscriber Login   

Aliskiren (ah LIS ker in; Tekturna – Novartis), the first direct renin inhibitor, has been approved by the FDA for treatment of hypertension. It is indicated for oral use either as monotherapy or in combination with other antihypertensive agents.

MECHANISM OF ACTION — Renin catalyzes the cleavage of angiotensinogen to form angiotensin I, the first and rate-limiting step of the renin-angiotensinaldosterone system (RAAS). Aliskiren binds renin, leading to reduced levels of angiotensin I, angiotensin II and aldosterone.

All drugs that inhibit RAAS, including aliskiren, can cause a compensatory increase in plasma renin concentrations (PRC), but unlike angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), aliskiren does not appear to increase plasma renin activity (PRA) because it binds renin with high affinity in plasma.1,2 In one pharmacokinetic ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Aliskiren (Tekturna) for Hypertension
Article code: 1258a
 Electronic, downloadable article - $25